Loading clinical trials...
Loading clinical trials...
Phase II Study of Combined Laronidase (AldurazymeTM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH)
Conditions
Interventions
Stem Cell Transplant
Laronidase ERT
Locations
1
United States
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
Start Date
March 1, 2004
Primary Completion Date
November 1, 2012
Completion Date
November 1, 2012
Last Updated
July 11, 2019
NCT02254863
NCT03488394
NCT05422482
NCT06333041
NCT03204370
NCT04453085
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions